TY - JOUR
T1 - Neuroprotective effect of bone marrow-derived mononuclear cells promoting functional recovery from spinal cord injury
AU - Yoshihara, Tomoyuki
AU - Ohta, Masayoshi
AU - Itokazu, Yutaka
AU - Matsumoto, Naoya
AU - Dezawa, Mari
AU - Suzuki, Yoshihisa
AU - Taguchi, Akihiko
AU - Watanabe, Yumi
AU - Adachi, Yasushi
AU - Ikehara, Susumu
AU - Sugimoto, Hisashi
AU - Ide, Chizuka
PY - 2007/6
Y1 - 2007/6
N2 - Neural cell transplantation, a new therapeutic strategy for replacing injured neural components and obtaining functional recovery, has shown beneficial effects in animal models. Use of this strategy in human patients, however, requires that a number of serious issues be addressed, including ethics, immunorejection, and the therapeutic time window within which the procedure will be effective. Bone marrow-derived mononuclear cells (BM-MNC) are attractive for transplantation because they can be used as an autograft, can be easily collected within a short time period, and do not have to be cultured. In a rat model of spinal cord injury (SCI), we transplanted BM-MNC at 1 h after SCI at Th 8-9 by injecting them into the cerebrospinal fluid (CSF), and investigated the effect of this on neurologic function. In the acute stage of injury, we found a neuroprotective antiapoptotic effect, with an elevated concentration of hepatocyte growth factor in CSF. At 1 week after transplantation, the Basso-Beattie-Bresnahan locomotor score had increased significantly over its baseline value. In the chronic stage of injury, we observed suppressed cavity formation and functional improvement. We conclude that transplantation of BM-MNC after SCI has a remarkable neuroprotective effect in the acute stage of injury, suppressing cavity formation, and contributing to functional recovery. Our results suggest that transplantation of BM-MNC via the CSF is a potentially effective means of enhancing functional recovery after SCI in humans.
AB - Neural cell transplantation, a new therapeutic strategy for replacing injured neural components and obtaining functional recovery, has shown beneficial effects in animal models. Use of this strategy in human patients, however, requires that a number of serious issues be addressed, including ethics, immunorejection, and the therapeutic time window within which the procedure will be effective. Bone marrow-derived mononuclear cells (BM-MNC) are attractive for transplantation because they can be used as an autograft, can be easily collected within a short time period, and do not have to be cultured. In a rat model of spinal cord injury (SCI), we transplanted BM-MNC at 1 h after SCI at Th 8-9 by injecting them into the cerebrospinal fluid (CSF), and investigated the effect of this on neurologic function. In the acute stage of injury, we found a neuroprotective antiapoptotic effect, with an elevated concentration of hepatocyte growth factor in CSF. At 1 week after transplantation, the Basso-Beattie-Bresnahan locomotor score had increased significantly over its baseline value. In the chronic stage of injury, we observed suppressed cavity formation and functional improvement. We conclude that transplantation of BM-MNC after SCI has a remarkable neuroprotective effect in the acute stage of injury, suppressing cavity formation, and contributing to functional recovery. Our results suggest that transplantation of BM-MNC via the CSF is a potentially effective means of enhancing functional recovery after SCI in humans.
KW - Bone marrow-derived mononuclear cell
KW - Cell transplantation
KW - Cerebrospinal fluid
KW - Neuroprotection
KW - Spinal cord injury
UR - http://www.scopus.com/inward/record.url?scp=34347326019&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34347326019&partnerID=8YFLogxK
U2 - 10.1089/neu.2007.132R
DO - 10.1089/neu.2007.132R
M3 - Article
C2 - 17600518
AN - SCOPUS:34347326019
SN - 0897-7151
VL - 24
SP - 1026
EP - 1036
JO - Journal of Neurotrauma
JF - Journal of Neurotrauma
IS - 6
ER -